Protara Therapeutics, Inc.
NASDAQ:TARABiotechnology
Healthcare
$2.34 -1.27%
-$0.05 today
- Market cap
- $144.07M
- Beta
- 1.45
- P/E (TTM)
- -2.7
- EPS (TTM)
- -$1.48
52W Low $2.77High $7.82
Volume 1.15M
Average 0.73M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$56.37M
FY 2025 · Annual
Investing Cash Flow
-$139.49M
FY 2025 · Annual
Financing Cash Flow
$82.72M
FY 2025 · Annual
-40.9% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (47.25M) | (65.95M) | (40.42M) | (44.6M) | (57.44M) |
| Depreciation & Amortization | 117K | 248K | 341K | 332K | 362K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 10.36M | 6.69M | 6.09M | 4.13M | 3.83M |
| Change in Working Capital | 534K | 539K | (4.14M) | 4.01M | (2.94M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 40K | 631K | 848K | 1.38M | (873K) |
| Other Working Capital | 494K | (92K) | (4.99M) | 2.63M | (2.07M) |
| Other Non-Cash Items | 1.74M | 32.02M | 569K | 324K | (173K) |
| Operating Cash Flow | (34.5M) | (26.46M) | (37.56M) | (35.81M) | (56.37M) |
| Capital Expenditures | (596K) | (120K) | (45K) | (63K) | (94K) |
| Acquisitions (Net) | 97.6K | (15.07K) | 0 | 0 | 0 |
| Purchases of Investments | (124.75M) | (43.55M) | (12.19M) | (29.38M) | (204.63M) |
| Sales of Investments | 27.15M | 58.62M | 65.34M | 48.6M | 65.23M |
| Other Investing Activities | (97.6K) | 15.07K | 0 | 0 | 0 |
| Investing Cash Flow | (98.19M) | 14.95M | 53.11M | 19.16M | (139.49M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 0 | 0 | 0 | 136.01M | 82.9M |
| Common Stock Repurchased | (228K) | (90K) | (91K) | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | 3.86M | (185K) |
| Financing Cash Flow | (228K) | (90K) | (91K) | 139.87M | 82.72M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (132.92M) | (11.6M) | 15.46M | 123.21M | (113.14M) |
| Free Cash Flow | (35.1M) | (26.58M) | (37.6M) | (35.87M) | (56.46M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$57.4M
+ D&A$362.0K
+ Stock-Based Comp$3.8M
+ Deferred Tax$0
- Working Capital-$2.9M
- Other Non-Cash-$173.0K
= Operating Cash Flow-$56.4M
- Capex-$94.0K
= Free Cash Flow-$56.5M
Analysis
FY2025 free cash flow is -$56.5M. FCF conversion is 98.3% of net income. Operating cash flow was -$56.4M, with capex of -$94.0K. The largest bridge item is Stock-Based Comp at $3.8M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 6, 2026 | |
| 10-Q | Quarterly report | Nov 6, 2026 | |
| SC 13G/A | SC 13G/A filing | Aug 13, 2026 | |
| 8-K | Current report | Aug 11, 2026 | |
| S-8 | S-8 filing | Aug 11, 2026 |
Does TARA generate free cash flow?
Protara Therapeutics, Inc. (TARA) generated -$56.46M of free cash flow in fiscal 2025.
How much operating cash flow does TARA produce?
Operating cash flow was -$56.37M, before capital expenditures of $94,000.00.
Continue the stock analysis
Jump to another research area for this company.